Clinical Trial Update: Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures [Phase 3]

View source ↗

Summary

A Phase 3 safety study of Rufinamide as add-on therapy for refractory partial seizures has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Partial Seizures

Drugs mentioned

• Rufinamide (Rufinamide)

Snippet

Sponsor: University of South Alabama | Conditions: Refractory Partial Seizures | Phase 3 | Status: WITHDRAWN